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Abstract
Earlier in the past century, infections were regarded as the most likely
cause of childhood B-cell precursor acute lymphoblastic leukemia (pB-ALL).
However, there is a lack of relevant biologic evidence supporting this hypothesis.
We present in vivo genetic evidence mechanistically connecting inherited
susceptibility to pB-ALL and postnatal infections by showing that pB-ALL was
initiated in Pax5 heterozygous mice only when they were exposed to common
pathogens. Strikingly, these murine pB-ALLs closely resemble the human
disease. Tumor exome sequencing revealed activating somatic, nonsynonymous
mutations of Jak3 as a second hit. Transplantation experiments and deep
sequencing suggest that inactivating mutations in Pax5 promote leukemogenesis
by creating an aberrant progenitor compartment that is susceptible to malignant
transformation through accumulation of secondary Jak3 mutations. Thus,
treatment of Pax5(+/-) leukemic cells with specific JAK1/3 inhibitors resulted in
increased apop...
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 ABSTRACT  Earlier in the past century, infections were regarded as the most likely cause of 
childhood B-cell precursor acute lymphoblastic leukemia (pB-ALL). However, there 
is a lack of relevant biologic evidence supporting this hypothesis. We present  in vivo genetic evidence 
mechanistically connecting inherited susceptibility to pB-ALL and postnatal infections by showing 
that pB-ALL was initiated in  Pax5 heterozygous mice only when they were exposed to common patho-
gens. Strikingly, these murine pB-ALLs closely resemble the human disease. Tumor exome sequencing 
revealed activating somatic, nonsynonymous mutations of  Jak3 as a second hit. Transplantation experi-
ments and deep sequencing suggest that inactivating mutations in  Pax5 promote leukemogenesis by 
creating an aberrant progenitor compartment that is susceptible to malignant transformation through 
accumulation of secondary  Jak3 mutations. Thus, treatment of  Pax5 +/− leukemic cells with speciﬁ c 
JAK1/3 inhibitors resulted in increased apoptosis. These results uncover the causal role of infection in 
pB-ALL development. 
 SIGNIFICANCE: These results demonstrate that delayed infection exposure is a causal factor in pB-ALL. 
Therefore, these ﬁ ndings have critical implications for the understanding of the pathogenesis of leukemia 
and for the development of novel therapies for this disease.  Cancer Discov; 5(12); 1328–43. ©2015 AACR. 
See related commentary by Greaves and Müschen, p. 1244. 
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 INTRODUCTION 
 Childhood B-cell precursor acute lymphoblastic leukemia 
(pB-ALL) is the most common cancer in childhood. The 
overall cure rate is excellent (approximately 90%); however, 
treatment is associated with severe toxic side effects and long-
term sequelae, and 20% of children still relapse and may later 
succumb to their disease. Preventional strategies are clearly 
superior to any therapy improvement. The prerequisite to 
develop these strategies is to discover the etiology of pB-ALL 
( 1 ). Somatic alterations of the lymphoid transcription factor 
gene  PAX5 are a hallmark of pB-ALL ( 2–4 ), and recent dis-
coveries of inherited mutations of  PAX5 in a new syndrome 
of susceptibility to pre–B-cell neoplasia have extended the 
role of  PAX5 alterations in the pathogenesis of pB-ALL ( 5, 
6 ). The presence of the inherited mutations of  PAX5 seems 
to produce a persistent and hidden preleukemic clone that 
may convert to pB-ALL in only 30% of the family members 
who carry the mutation ( 5 ). Thus, the  PAX5 syndrome shows 
incomplete penetrance, and the mechanisms responsible for 
the conversion of the preleukemic clone into full-blown 
pB-ALL are not known. 
 Over the past century, infections have been regarded as the 
most likely cause of childhood leukemia ( 7 ). In 1988, two spe-
ciﬁ c hypotheses were proposed that implicated infection as 
an important causal factor in childhood leukemia: the Kinlen 
“population-mixing” hypothesis ( 8 ) and the “delayed-infec-
tion” hypothesis ( 9 ). Although the two hypotheses differ in 
detail and hypothetical mechanism, they do share common 
ground, as both postulate that childhood leukemia is a con-
sequence of a rare response to common infections ( 1 ). These 
studies suggested that the lack of timely exposure to infec-
tions in postnatal life in the clean environments of developed 
societies might predispose the immune system to aberrant 
or pathologic responses following subsequent or “delayed” 
exposure to common pathogens. Descriptive epidemiologic 
studies support infection as a causal factor in childhood 
leukemia ( 10, 11 ). However, there is no evidence supporting 
delayed exposure to infection as a second hit related to the 
natural history of the disease with prenatal initiation ( 1 ). 
Integrating these conﬂ icting data has proven challenging. 
 In this work, we have explored the role of infections in the 
development of pB-ALL using a  Pax5 heterozygous model, as 
recently germline mutations in  PAX5 have been described as con-
ferring an inherited risk to pB-ALL in three kindreds from differ-
ent ethnic backgrounds ( 5, 6 ). We present  in vivo genetic evidence 
mechanistically connecting inherited susceptibility to pB-ALL 
and postnatal infections by showing that pB-ALL was initiated in 
 Pax5 +/− mice only when they were exposed to common pathogens. 
Strikingly, these pB-ALLs closely resemble the human disease in 
pathology, genomic lesions, and leukemia-associated transcripts. 
Transplantation experiments and deep sequencing suggest that 
inactivating mutations in  Pax5 promote leukemogenesis by cre-
ating an aberrant progenitor compartment that is suscepti-
ble to malignant transformation through the accumulation of 
secondary  Jak3 mutations. Therefore, this model proves for the 
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ﬁ rst time that delayed exposure to infection triggers pB-ALL 
development. 
 RESULTS 
 Exposure to Common Pathogens Generates 
pB-ALL in  Pax5 +/− Mice 
 Recently, germline mutations in  PAX5 have been described 
as conferring an inherited risk for pB-ALL in three kin-
dreds from different ethnical backgrounds ( 5, 6 ).  Pax5 is 
required for normal B-cell development ( 12–15 ), although 
 Pax5 heterozygous mice do not spontaneously develop pB-
ALL ( 16 ). Thus, we initially asked if we could provoke pB-ALL 
development in  Pax5 +/− mice by exposing them to common 
pathogens. To test this hypothesis, the ﬁ rst group was com-
posed of  Pax5 +/− mice and control littermate wild-type (WT) 
mice born and kept in a speciﬁ c pathogen-free (SPF) envi-
ronment during their lifespan. These  Pax5 +/− mice did not 
spontaneously develop pB-ALL after 2 years, corroborating 
previous results ( 16, 17 ). The second group was composed of 
 Pax5 +/− mice and control littermate WT mice born and kept 
in the SPF environment until moved to a common infec-
tious environment ( Fig. 1A ). The microbiologic status in the 
conventional facility was deﬁ ned and controlled for 2 years 
(Supplementary Table S1; Supplementary Fig.  S1). Under 
this scenario, speciﬁ c pB-ALL development was observed in 
22% (9 of 41) of  Pax5 +/− animals but not in WT mice ( Fig. 1B, 
C, and D ), closely resembling the low penetrance of pB-ALL 
development in the families with the heterozygous  PAX5 
c.547G>A mutation ( 5, 6 ). The appearance of leukemia in 
 Pax5 +/− mice occurred between 6 and 16 months of age. This 
is independent of a crucial time point of exposure to infec-
tion, as pB-ALL appeared in mice that were transferred to 
a conventional animal facility between 2 and 5 months of 
age. These pB-ALLs became manifest with splenomegaly, 
disruption of splenic architecture due to blast inﬁ ltration, 
and appearance of blast cells in the peripheral blood (PB; 
 Fig.  1C ). FACS analysis revealed a cell surface phenotype 
of CD19 +/− B220 + IgM − cKIT +/− CD25 +/− for tumor cells that 
extended through bone marrow (BM), PB, spleen, and lymph 
nodes ( Fig. 1D ; Supplementary Fig. S2A and S2B) and inﬁ l-
trated nonlymphoid tissues like liver, kidney, and lung (Sup-
plementary Fig. S2C). All pB-ALLs displayed clonal immature 
B-cell receptor (BCR) rearrangement ( Fig. 1E ). To explore the 
relevance of our ﬁ ndings for human leukemia, we next iden-
tiﬁ ed 4,511 signiﬁ cantly repressed and 3,929 signiﬁ cantly 
induced genes (FDR  = 0.005) in tumor-bearing BM from 
 Pax5 +/− mice compared with BM-derived B220 + cells from 
WT mice ( Fig.  2A , left; Supplementary Table S2), includ-
ing increased expression of genes with roles in progenitor 
and stem cell compartments of BM and with signiﬁ cant 
enrichment in human B-ALL gene sets [refs.  18, 19 ; Gene Set 
Enrichment Analysis (GSEA) FDR = 0.000; FDR = 0.000] as 
well as signiﬁ cant alignment with the pro–B-cell stage of dif-
ferentiation (refs.  20, 21 ; GSEA up genes FDR = 0.000; down 
genes FDR = 0.000; Supplementary Fig. S2D). In order to rule 
out that the heterogeneity of the control B cells could also 
contribute to the observed differential gene expression, we 
characterized the global expression signature of puriﬁ ed WT 
pro/pre-B cells and compared with the expression signature 
of  Pax5 +/− leukemias. The analysis showed a similar differen-
tial gene expression proﬁ le ( Fig. 2A , right). 
 The universal ﬁ nding of deletion of the WT  PAX5 allele 
and retention of the hypomorphic  PAX5 c.547G>A allele in 
human pB-ALL suggests that very reduced activity of WT 
PAX5 is required to establish the leukemic clone ( 6 ). Thus, 
we next investigated the status of  Pax5 in mouse pB-ALL. The 
majority of the murine  Pax5 +/− pB-ALL (5/9; 55.6%) did not 
express CD19 ( Table 1 ), suggesting loss or marked reduction 
of  Pax5 activity, which is in agreement with gene expres-
sion analysis of murine  Pax5 +/− tumors showing reduced 
transcriptional activity of PAX5, similar to what is found in 
human leukemia (refs.  5, 6 ; Supplementary Fig.  S2E; Sup-
plementary Tables S2 and S3). In this sense, whole-exome 
sequencing analysis of 8 of 9  Pax5 +/− pB-ALL identiﬁ ed two 
cases involving the acquisition of an additional  Pax5 muta-
tion, which were the presence of a  Pax5 variant, p.Pro80Arg 
( 2 ), causing reduced PAX5 transcriptional activity in humans 
and a second  Pax5 variant, p.Pro80Leu. However, our ﬁ nding 
that 4 murine pB-ALL tumor cells expressed CD19 ( Table 1 ) 
suggests that a complete loss of PAX5 activity is not required 
to establish the leukemic clone in a signiﬁ cant percentage 
of cases. In addition, in 100% of cases these human pB-ALLs 
displayed homozygous loss of the  CDKN2A ( p19ARF/
INK4A ) tumor suppressor locus ( 5, 6 ). In 2 of 5 murine pB-
ALLs,  p19Arf expression was absent ( Fig.  2B ), correlating in 
one mouse (O361) with genomic loss of the  Cdkn2a locus 
( Fig.  2C ). Overall, these results provide evidence that this 
murine model closely reproduces the human disease pheno-
type with respect to clinical and molecular/genetic aspects. It 
represents the ﬁ rst proof that delayed exposure to infection 
can induce human-like pB-ALL in mice with an inherited 
genetic predisposition at reduced penetrance. 
 Exposure to Infection in  Pax5 +/− 
pB-ALL Development 
 To identify the types of pathogens in the conventional 
facility, we monitored the health status of the respective ani-
mals. In the SPF facility, animals are pathogen free according 
to the serological analysis carried out (Supplementary Table 
S1). When transferred to the conventional animal facility, 
mice are exposed to a variety of pathogens, among them 
murine norovirus, mouse hepatitis virus, helicobacter species, 
and trichomonas muris (Supplementary Fig.  S1), inciting 
a signiﬁ cant immune response in the animals. In order to 
exclude insertional mutagenesis and leukemia development 
on the basis of viral integration, we carried out whole-genome 
sequencing of three  Pax5 +/− pB-ALLs. This experimental 
approach was very sensitive as it was able to detect a sin-
gle 127 bp integration into exon 2 of the  Pax5 locus in all 
three tumor samples and control mice. This is the SV40 
nuclear localization signal inserted together with the target-
ing vector into  Pax5 exon 2 for generation of the  Pax5 –/− mice 
( 15 ). The sequence serves as positive control to prove this 
approach is able to identify a small single virus copy within 
the genome. In addition, we did not observe viral integration 
close to proto-oncogenes ruling out pB-ALL development 
based on insertional mutagenesis, providing evidence against 
direct viral transformation in agreement with observations in 
human pB-ALL ( 22 ). 
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 Figure 1.   Pax5 heterozygosity and exposure to infectious stimuli cooperate in pB-ALL development. A, experimental setup. Mice are born under SPF 
conditions and are moved to a non-SPF facility where they are exposed to common infectious pathogens between 5 and 21 weeks after birth. B, pB-ALL–
speciﬁ c survival curve of  Pax5 +/− animals in SPF conditions (red,  n = 14) compared with WT control mice (black,  n = 15), close to pB-ALL–speciﬁ c 
survival curve of  Pax5 +/− animals in non-SPF conditions (red,  n = 41) compared with WT control mice (black,  n = 20), showing a signiﬁ cantly (log-rank 
 P value 0.0098) shortened life span (right). C, example of splenomegaly observed in 55% (5 of 9) of  Pax5 +/− mice. WT mouse spleen is shown for refer-
ence. Hematoxylin and eosin staining of spleen sections from WT- and tumor-bearing  Pax5 +/− mice shows inﬁ ltrating blast cells. Scale bar, 10 μm (= 400×;
 n = 9). D, ﬂ ow cytometric analysis of hematopoietic subsets in diseased  Pax5 +/− mice. Representative plots of cell subsets from the BM and PB show 
accumulation of blast B cells in  Pax5 +/− mice ( n = 9; age, 6–16 months) compared with control littermate age-matched WT mice ( n = 4; age, 8–16 months). 
E, immunoglobulin clonality in  Pax5 +/− tissues inﬁ ltrated with blast B cells. PCR analysis of immunoglobulin heavy-chain gene rearrangements in inﬁ l-
trated spleens and lymph nodes of diseased  Pax5 +/− mice. Thymocytes (T cells) were included as a negative control, and sorted CD19 + B cells (B cells) 
from the spleens of healthy mice serve as a control for polyclonal BCR rearrangements (indicated by numbers 1–4). Inﬁ ltrated tissues show an increased 
clonality within their immunoglobulin repertoire (red squares;  n = 2).  
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 Figure 2.   pB-ALLs from  Pax5 +/− mice resemble human pB-ALL. A, differential gene expression analysis of tumor-bearing BMs of three  Pax5 +/− mice 
(O361, W634, and S748 CD19 + phenotype; S665, O388, and W362 CD19 − phenotype) compared with B220 + BM B cells from ﬁ ve WT mice shows 
signiﬁ cant differences (left). In the right plot, differential gene expression analysis of tumor-bearing BMs of six  Pax5 +/− mice compared with BM pro-B 
and pre-B cells from three WT mice shows signiﬁ cant differences (FDR = 0.01). B, relative expression of  p19Arf from BM tumor cells of  Pax5 +/− mice 
(samples 1–5). Total BM of a SCA1-BCR–ABL-p210 mouse was used as a positive control (sample 6). Blast cells of  Pax5 +/− mice 1, 2, and 3 are CD19 − , and 
blast cells of  Pax5 +/− mice 4 and 5 are CD19 + . Error bars represent the mean ± SD of three replicates. C, loss of  Cdkn2a locus from all tumor/reference pairs. 
Copy-number variation proﬁ les were calculated using Free copy number and genotype caller (FREEC) . Copy-number proﬁ les displayed a loss of heterozygos-
ity at 4:89274500-89276999 in mouse O361.  
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 Table 1.   Genotype and phenotype of pB-ALL–bearing Pax5 +/− mice 
Mouse 
number
Mouse age 
at disease 
(months)
CD19 
phenotype
 Jak3 
mutation 
in mouse a 
 Jak3 mutation 
(allele frequency) b 
 JAK3 human 
homolog
 Pax5 
mutation 
in mouse a 
 PAX5 
human 
homolog
 Jak1 
mutation in 
mouse a 
1 O361  8.8 CD19 + R653H R653H (50%) R657Q S645P
2 O388  9.5 CD19 − R653H R653H (11%) R657Q —
3 S665  6.5 CD19 − — R563H (2%) R657Q P80R P80R V657F
4 O332 15.3 CD19 − — — — —
5 W495 10.2 CD19 − — — — —
6 S748 14.2 CD19 + V670A V670A (27%) V674A P80L Not 
described
—
7 W893  9.8 CD19 − R653H R653H (49%) R657Q —
8 S767 15.3 CD19 + R653C R653C (63%) R657Q —
9 W634 12 CD19 + R653H R653H (35%) R657Q —
 a Mutations conﬁ rmed by Sanger sequencing.
 b Mutations conﬁ rmed by deep sequencing. 
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 Figure 3.   B-cell development in young  Pax5 +/− mice. A, percentage of PB B cells (B220 + IgM +/− ) at different time points in  Pax5 +/− mice ( n = 12) compared 
with WT mice ( n = 22) analyzed by ﬂ ow cytometry. A signiﬁ cant decrease in PB B cells can be observed in  Pax5 +/− mice at 3, 6, and 9 months of age. Error bars 
represent the SD.  t test  P value is indicated in each case. Four-month-old  Pax5 +/− mice ( n = 8) show increased numbers of pre-B/pro-B cells (B220 low IgM − ) and 
immature B cells (B220 low IgM + ) compared with age-matched WT mice ( n = 4) but not recirculating B cells (B220 ++ IgM + ). Unpaired  t test  P value is indicated in 
each case. (continued on next page)
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Precursor B-cell Compartment 
 We next aimed to explain the mechanism of this speciﬁ c 
pB-ALL susceptibility due to  Pax5 heterozygosity under expo-
sure to infections. To this end, the different B-cell developmental 
stages were analyzed in WT and preleukemic  Pax5 +/− littermates 
of the same breeding.  Pax5 +/− mice presented a signiﬁ cantly 
reduced amount of total B cells in the PB when compared 
with WT mice ( Fig.  3A ; Supplementary Table S4). This 
decrease was not induced by the exposure to common patho-
gens, as a similar decrease in PB B cells was observed in 
 Pax5 +/− mice housed in an SPF environment ( Fig. 3B ). On the 
other hand, we observed signiﬁ cantly higher proportions of 
(pro+pre)-B and immature B cells in the BM of  Pax5 +/− mice 
compared with age-matched WT littermates ( Fig.  3A ; Sup-
plementary Table S4), but no differences were detected in 
earlier developmental compartments of the BM (data not 
shown). These data therefore suggest that  Pax5 heterozy-
gosity favors the appearance of an aberrant B-cell precursor 
compartment in the BM and that differentiation to mature 
PB B cells is impaired  in vivo in keeping with observations in 
 Pax5 -null mice ( 13 ) and in a stable  in vivo Pax5 knockdown 
model ( 23 ). These observations are in agreement with reports 
of preleukemic activity in mice bearing pB-ALL–associated 
oncogenes, e.g., the  ETV6–RUNX1 fusion ( 24, 25 ). The murine 
precursor B cells are dependent on intact IL7/IL7R signaling 
and subsequent activation of JAK3 and STAT5 phosphoryla-
tion. Thus, we next explored the response of  Pax5 +/− pro-B 
cells to IL7 withdrawal and showed that  Pax5 +/− pro-B cells 
are more sensitive to IL7 withdrawal than their WT counter-
parts ( Fig. 3C ). Similar observations were obtained when pre-
leukemic  Pax5 +/− pro-B cells were exposed to speciﬁ c JAK1/3 
inhibitors ( Fig. 3D ). Taken together, these results imply that 
aberrant precursors present in  Pax5 +/− mice are extremely 
sensitive to IL7 withdrawal and susceptible for second hits 
leading to leukemia development. 
 Mouse Tumor Exome Sequencing Data Identify the 
Second Hit within the IL7R/JAK3/STAT5 Axis 
 In order to identify the second hit related to pB-ALL 
disease with prenatal initiation triggered by infection expo-
sure in the context of impaired B-cell development, we next 
performed whole-exome sequencing of three  Pax5 +/− tumors 
and corresponding germline samples on a HiSeq 2500 (Illu-
mina) platform.  Pax5 +/− tumor cells were derived from BM 
of diseased mice. We identiﬁ ed between 28,638 and 31,105 
single-nucleotide variations (SNV) in tumor samples and 
between 27,141 and 31,151 SNVs in germline samples, 
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 Figure 3. (Continued) B, decrease in PB B cells in  Pax5 +/− mice housed in SPF conditions. Percentage of PB B cells in  Pax5 +/− mice ( n = 10) compared with 
WT mice ( n = 10) analyzed by ﬂ ow cytometry as B220 + IgM +/− cells at 3 and 6 months of age. Error bars represent the mean ± SD. Unpaired  t test  P value is indi-
cated in each case. A signiﬁ cant decrease in PB B cells can be observed in  Pax5 +/− mice housed in SPF conditions. C, cell death susceptibility mediated by IL7 
removal in  Pax5 +/− pro-B cells. Sorted B220 + cells from BM of young  Pax5 +/− and WT mice were cultured under conditions to allow the isolation and expansion 
of a pure population of pro-B cells. Pro-B cells were cultured with or without IL7 for 24 hours. Induction of apoptosis was assessed by ﬂ ow cytometry using 
Annexin V/PI staining. Data represent the mean ± SD of normalized apoptotic cells from six independent experiments. Unpaired  t test  P value is indicated in 
each case. D, cell death mediated by JAK inhibitors in WT and  Pax5 +/− pro-B cells. IL7-dependent pro-B cells were cultured with tofacitinib (JAK1/3 inhibitor; 1 
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etry using Annexin V/PI staining. Graphs indicate the fold change of dead cells treated with the inhibitor in each experiment compared with cells treated with 
the vehicle. Data represent the mean ± SD from three independent experiments. Unpaired  t test  P value is indicated in each case.  
resulting in 31 (O361; CD19 + ), 17 (O388; CD19 − ), and 9 
(S665; CD19 − ) somatic SNVs in the three mice. Finally, 
we detected  Jak3 c.1958G>A (p. R653H) as one recurrent 
heterozygous nonsynonymous somatic SNV in the pseu-
dokinase domain of JAK3 in two mice ( Fig.  4A ; Supple-
mentary Table S5). The corresponding human homolog 
( JAK3 R657Q ) is recorded in the cancer gene consensus data-
base (ref.  26 ;  Table 1 ). Next, we applied Sanger sequencing 
to the remaining tumors and, surprisingly, we identiﬁ ed 
nonsynonymous  Jak3 mutations in 6 of 9 mice causing 
 Jak3 R653H (4/9; human homolog  JAK3 R657Q ),  Jak3 R653C (1/9; 
human homolog  JAK3 R657Q ), and  Jak3 V670A (1/9; human 
homolog  JAK3 V674A ; data not shown). This result and the 
fact that all  Jak3 variants (R653H, R653C, and V670A) are 
located in a region highly conserved across different species 
together indicate that these variants are relevant for leuke-
mia evolution ( Table 1 ). We next performed deep sequencing 
with a depth between 600,000 and 2.5 × 10 6 reads per  Jak3 
SNV and observed the nonsynonymous  Jak3 variant only in 
tumor samples but not in BM cells of healthy  Pax5 +/− or WT 
mice ( Fig. 4B ). In addition, in mice S748 ( Jak 3 V670A ), W634 
( Jak 3 R653H ), and S767 ( Jak 3 R653C ), we were able to monitor 
leukemia evolution over time by collecting peripheral blood 
mononuclear cells (PBMC) at routine intervals after birth 
using deep sequencing at the same depth as described above. 
All  Jak3 variants were ﬁ rst detectable by deep sequencing 
and Sanger sequencing when the mouse appeared clinically 
ill with pB-ALL ( Fig. 4C ). This result is incompatible with a 
model in which  Jak3 mutations are present in few cells from 
birth on and become selected over time. Instead, they are  de 
novo mutations occurring on the  Pax5 +/− background as a 
consequence of environmentally driven selection pressure 
with a very short latency to leukemia outgrowth. 
 Somatic  Jak3 Mutations Rescue IL7-Sensitive 
 Pax5 +/− Precursor B Cells and Cause Leukemia 
Outgrowth 
 The corresponding human  JAK3 R657Q and  JAK3 V674A 
variants result in constitutive kinase activity of JAK3 and 
downstream STAT5 phosphorylation ( 27, 28 ). Hence, we 
transfected IL3-dependent Ba/F3 cells with the murine 
 Jak3 R653H variant and observed cytokine-independent growth 
( Fig. 4D ), consistent with phosphorylation of STAT5 in the 
absence of IL3 ( Fig. 4E ). Similarly, we observed STAT5 phos-
phorylation in the mouse leukemic cells carrying  Jak3 V670A 
( Fig. 4F ). Consistently, tumor pro-B cells harboring  Jak3 V670A 
and  Jak3 R653H grow independent of IL7 ( Fig.  4G, H, and I ). 
In two pB-ALLs (O361 and S665), we additionally identiﬁ ed 
 Jak1 mutations ( Table 1 ). JAK3 pseudokinase mutants are 
dependent on JAK1 kinase activity for cellular transformation 
( 29 ). This is consistent with the increase in cell death after 
administration of the JAK1/2 inhibitor ruxolitinib  in vitro 
( Fig. 4J ) as well as the decrease in leukemic cell burden  in vivo 
(see below). 
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 To identify the tumor repopulating cells of the murine 
 Pax5 +/− pB-ALL, we transplanted primary myeloid cells, 
 Pax5 +/− pro-B cells harboring WT  Jak3 , and  Pax5 +/− pro-B cells 
harboring  Jak3 V670A , respectively, into sublethally irradiated 
syngeneic recipient mice. Each of the mice transplanted ( n = 9) 
with 10 5 Pax5 +/− pro-B cells harboring  Jak3 V670A cells devel-
oped a pB-ALL with a latency of 13 ± 3 days. The disease was 
phenotypically identical to the primary disease. In contrast, 
when recipient mice were transplanted with myeloid cells 
( n = 7; 10 6 cells per mouse) and  Pax5 +/− pro-B cells ( n = 10; 
10 5 cells per mouse), they were incapable of inducing pB-
ALL in secondary recipients ( Fig. 5A–C ). This indicates that 
infection-induced  Pax5 +/− pB-ALL in this model is propagated 
by transformed  Pax5 +/− pro-B cells harboring  Jak3 V670A but 
not  Pax5 +/− pro-B cells harboring WT  Jak3 , and conﬁ rms that 
 Jak3 V670A can induce pB-ALL in mice. These results suggested 
that the  Pax5 heterozygous condition can establish the envi-
ronment for the generation of the  Jak3 mutation and is not 
playing a role in the pathogenesis of the ﬁ nal leukemia. Thus, 
we next examined the PAX5-independent potential role of 
the identiﬁ ed  Jak3 mutations in leukemogenesis by injecting 
10 6 Ba/F3 cells expressing either  Jak3 V670A ( n = 5) or  Jak3 R653H 
( n = 4) mutants in nude mice, and we monitored the pB-ALL 
development by periodic analysis of the presence of blast 
cells in PB. The results show that both mutants are able to 
generate pB-ALL in mice with a disease latency of 27 ± 3 days 
(Supplementary Fig. S3A–S3C), suggesting that inactivating 
mutations in  Pax5 promote leukemogenesis by simply creat-
ing an aberrant IL7-sensitive progenitor compartment that is 
susceptible to malignant transformation through accumula-
tion of secondary  Jak3 mutations as a rescue mechanism of 
IL7/IL7R/STAT5 signaling. 
 Successful  In Vivo Treatment of  Pax5 +/− pB-ALL 
Using JAK Inhibitors 
 These results suggest that JAK1/3 inhibitors may be use-
ful therapeutic options for pB-ALL in patients with germ-
line  PAX5 mutations. Thus, we treated tumor pro-B cells 
( Jak3 V670A ) with three different selective JAK inhibitors: tofac-
itinib (JAK1/3), TG101348 (JAK2), and ruxolitinib (JAK1/2). 
Tumor pro-B cells were sensitive to the JAK1/3 and the JAK1/2 
inhibitors but not to the JAK2 inhibitor  in vitro ( Fig. 4J ). 
 We next tested the efﬁ cacy of the JAK inhibitors  in vivo . 
To this end, mice infused with transformed  Pax5 +/− pro-B 
cells harboring  Jak3 V670A were randomized to treatment at 
day 12 when the disease was conﬁ rmed by the presence of 
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blast cells in the PB of the reconstituted mice ( Fig. 6A ). Mice 
were treated with ruxolitinib for only 5 days. FACS analysis 
of the PB was used to verify disease remission after therapy. 
Although ruxolitinib provided no signiﬁ cant survival advan-
tage, all mice treated ( n = 5) showed a transient decrease in 
the blast cells ( Fig.  6B ). However , disseminated leukemia, 
documented by clinical criteria and FACS ( Fig.  6C and D ), 
invariably ensued, except in 1 of 5 mice that was alive and 
healthy 33 days after discontinuation of treatment, when the 
mouse was sacriﬁ ced, and FACS analysis conﬁ rmed that blast 
cells were not present in the BM (Supplementary Fig. S3D). 
In summary, these data further suggest that  Jak3 mutations 
retain driver functions in established leukemia. Thus, target-
ing the deregulated JAK–STAT pathway could be a promising 
therapy for this disease. 
 DISCUSSION 
 The common belief in childhood pB-ALL development 
is that children with intrinsic genetic susceptibility to 
pB-ALL development acquire additional chromosomal aber-
rations, i.e.,  ETV6–RUNX1 —most of them  in utero during fetal 
hematopoiesis—as a primary pathogenetic event followed by 
a broad range of secondary mutational events resulting in a 
full-blown leukemia. Common among these secondary events 
are alterations disrupting the  PAX5 gene, which encodes 
a master transcriptional regulator of B-cell development 
( 13, 14 ). In this setting, PAX5 seems to retain driver functions 
in established leukemia because restoring endogenous PAX5 
expression triggers disease remission ( 23 ). 
 Recent discoveries of inherited mutations of  PAX5 in a 
new syndrome of susceptibility to pB-ALL have extended the 
role of  PAX5 alterations in the pathogenesis of pB-ALL ( 5, 
6 ). The presence of the inherited mutations of  PAX5 seems 
to produce a persistent and hidden preleukemic clone that 
may convert to pB-ALL in only a fraction of the family mem-
bers ( 5, 6 ). The patients lose the WT  PAX5 allele related to a 
secondary structural aberration of chromosome 9p. In mice, 
we face the same scenario, but the sequence is reverse. The 
mice have lost one WT  Pax5 allele and acquire  Pax5 point 
mutations as secondary events. However, the ﬁ nal common 
path in both species is reduced transcriptional activity of 
PAX5. The mechanisms responsible for the conversion of the 
preleukemic clone, carrying the inherited mutations of  PAX5 , 
G
E F
H I J
Em
pty
 ve
cto
r
JA
K3
 W
T
pSTAT5
STAT5
30 Pax5+/–
Pax5+/– + Jak3V670A
WT25
20
15
10
5
0
0 1 2
Time in IL7 free medium (days)
To
ta
l c
el
l n
u
m
be
r (
×
10
4 )
3 4 5 6 7
β-Actin
pSTAT5
STAT5
G
er
m
lin
e
Pr
o-
B 
ce
lls
 p
B-
AL
L
ge
no
m
ic
S748
c.2009T>C
p.670V>A
c.1958G>A
p.653R>H
W634
β-Actin
JA
K3
R6
53
H
No
t tr
an
sfe
cte
d
S7
48
WT
106
105
104
103
102
102 103
B2
20
W
ith
 IL
7
W
ith
ou
t I
L7
B2
20
B2
20
B2
20
IgM
IgM CD19
CD19
104 105 106
106
105
104
103
102
102 103 104 105 106
106
105
104
103
102
102 103 104 105 106
106
105
104
103
102
102 103 104 105 106
1.4
P value = 0.0045
P value = 0.0003
**
***
1.3
1.2
1.1
1.0
0.9
(JA
K1
/3 i
nhi
bito
r)
(JA
K2
 inh
ibit
or)
(JA
K1
/2 i
nhi
bito
r)
Ve
hic
leF
o
ld
 c
ha
ng
e 
in
 d
ea
d 
ce
lls
G G G GC A ATT T
G G G GC A AYT T G G GC C RT T
G C C G G GTT
Mouse S748
 Figure 4. (Continued) E, transfected cells were cultivated in media without IL3 and serum for 4 hours, before being subjected to immunoblot analysis 
for phosphorylated (p) STAT5, as well as total STAT5 and β-actin as loading controls ( n = 2, shown is one representative experiment). F, lysate of spleen 
tumor cells (S748), harboring  Jak3 V670A , was subjected to immunoblot analysis for pSTAT5, total STAT5, and β-actin. Tumor cells show constitutive pSTAT5 
activation ( n = 2). G, immunophenotype of tumor  Pax5 +/− pro-B cells harboring  Jak3 V670A . Sorted B220 + cells from BM of the diseased  Pax5 +/− mouse were 
cultured under conditions to allow the isolation and expansion of a pure population of pro-B cells and grow in the absence of IL7 due to the activating 
 Jak3 V670A mutation. H, WT,  Pax5 +/− , and  Pax5 +/−  Jak3 V670A primary pro-B cells were cultured in media without IL7. Proliferation was measured using Trypan 
Blue. Values represent the mean out of three replicates with essentially identical datasets. I, Sanger sequencing of leukemic pro-B cells of mice S748 and 
W634, grown  in vitro without IL7, validating the variants  Jak3 V670A and  Jak3 R653H , respectively ( n = 2). J, tumor  Pax5 +/− pro-B cells harbor the  Jak3 V670A 
mutation and grow independently of IL7. Pro-B cells were cultured with tofacitinib (1 μmol/L), TG101348 (1 μmol/L), and ruxolitinib (1 μmol/L) for 24 
hours. Induction of apoptosis was assessed by ﬂ ow cytometry using Annexin V/PI staining. Graph indicates the fold change of dead cells in each experi-
ment. Data represent the mean ± SD from at least three independent experiments. Unpaired  t test  P value is indicated.  
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 Figure 5.   pB-ALL is transplantable to secondary recipients. A, experimental setup. A total of 100,000 leukemic  Pax5 +/− pro-B cells harboring  Jak3 V670A  
mutation were injected into sublethally irradiated WT syngeneic mice. Regular bleedings were performed in order to monitor the development of the 
pB-ALL. B, representative ﬂ ow cytometric analysis of mice injected with leukemic  Pax5 +/− proB cells harboring  Jak3 V670 mutation. Cytometric analyses at 
different time points show that leukemic pB-ALL cells (B220 lo IgM − ) were able to grow in secondary recipients. BMT, bone marrow transplant. C, repre-
sentative ﬂ ow cytometric analysis of mice injected with leukemic  Pax5 +/− proB cells harboring  Jak3 V670A mutation shows the accumulation of pB-ALL cells 
(B220 lo IgM − ) in BM. FSC-A, forward scatter-area; SSC-A, side scatter-area.  
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into pB-ALL are not understood yet. However, recent results 
suggest that the B-cell–speciﬁ c enzyme AID is supposed to 
be the predominant driver of clonal evolution in human 
ETV6–RUNX1 pB-ALL ( 30–32 ) and B-cell lymphoma ( 33 ). 
These observations are in line with previous studies showing 
that AID is capable of initiating aberrant genomic alterations 
in precursor B cells ( 34 ) The pB-ALL that originated as a 
result of delayed infection exposure in  Pax5 +/− mice offers a 
unique possibility to conﬁ rm if the proposed mechanisms 
are involved in the conversion of the preleukemic clone 
into a full-blown leukemia ( 35, 36 ). The assumption of a 
functional interaction between inherited susceptibility and 
postnatal infection is a highly attractive explanation in the 
natural history of childhood ALL. Our results bring strong 
functional proof in support of the “infectious” hypothesis 
that posits that exposure to infection represents an onco-
genic environment that promotes leukemia development. In 
our experimental model,  Pax5 +/− mice never develop leuke-
mia in a pathogen-free environment. However, exposure of 
 Pax5 +/− mice to infectious stimuli at the age of 2 to 5 months 
represents the necessary oncogenic environment. Hence, this 
observation closely mimics the human situation. Children 
encounter a plethora of different infectious agents at the ages 
of 2 to 5 years, but all attempts to identify a single consistent 
infectious agent have failed in humans with pB-ALL ( 11 ). 
This indicates that it is a sequence of infections and broad 
immune responses in an unprimed immune system, which is 
important for leukemia development, rather than exposure 
to a single pathogen. Likewise, several months prior to ALL, 
children show a marked deterioration of immune response 
and profound liability to a variety of infections ( 35 ). 
 In our model, inactivating mutations in  Pax5 promote 
leukemogenesis by creating an aberrant IL7-sensitive progeni-
tor compartment. This progenitor population is susceptible 
to malignant transformation through accumulation of sec-
ondary  Jak3 mutations on the basis of a selection pressure 
triggered by the increased and recurrent exposure to delayed 
infection in conventional housing facilities. These somatic 
 Jak3 mutations induce leukemia with a phenotype very simi-
lar to the human pB-ALL linked to germline  mutations 
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in  PAX5 with respect to clinical, immunophenotypic, and 
molecular genetic characteristics.  In vivo transplantation 
experiments demonstrate that the activating  Jak3 mutations 
 per se are sufﬁ cient to drive leukemia. Thus, targeting the 
deregulated JAK–STAT pathway can be a promising therapy 
for this disease, as we have shown  in vivo . 
 Strikingly, this model parallels very well the incomplete 
penetrance observed in human  PAX5 +/− leukemia. Further 
studies with  Pax 5 +/− mice exposed to the same infectious 
conditions  in utero and in the ﬁ rst month of their life will 
reveal if the timing and pattern of infectious exposure are 
indeed relevant for pB-ALL development. This suggestion 
was rendered moot over 70 years ago ( 37 ). Toward this 
development, our ﬁ ndings are important not only for 
endorsing the credibility of the “infectious” hypothesis, 
but also for encouraging the prospect of novel interven-
tions that might help to prevent a signiﬁ cant proportion of 
childhood leukemia. 
 Figure 6.   In vivo efﬁ cacy of JAK inhibition in transformed  Pax5 +/− pro-B cells harboring  Jak3 V670A . A, experimental setup. A total of 100,000 leukemic 
 Pax5 +/− pro-B cells harboring  Jak3 V670A mutation were injected into sublethally irradiated WT syngeneic mice. Regular bleedings were performed in 
order to check the development of the pB-ALL. When pB-ALL cells (B220 lo IgM − ) were detected in the PB, the mouse treatment with ruxolitinib started. 
Mice were treated with ruxolitinib for only 5 days. FACS analysis of the PB was used to verify disease remission after therapy. B, percentage of PB 
pB-ALL cells (B220 lo IgM − ) was monitored by ﬂ ow cytometry at different time points in mice treated with ruxolitinib (ruxo). C, follow-up of leukemic cells 
(B220 lo IgM − ) by PB ﬂ ow cytometry in mice before and after ruxolitinib treatment. Mice treated with ruxolitinib showed a transient decrease in the blast 
cells except in mouse D009, which was alive and healthy 33 days after discontinuation of treatment. D, representative disseminated leukemia docu-
mented by FACS analysis of the BM of mice 5 days after starting treatment with ruxolitinib.  
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 METHODS 
 Heterozygous Pax5 +/− Mice 
 The heterozygous  Pax5 +/− mice ( 15 ) have been described previously. 
 Pax5 +/− and control WT mice were born and kept at the SPF facility 
until exposed to a common infectious environment. All animal work 
was conducted according to relevant national and international 
guidelines, and it has been approved by the Bioethics Committee of 
the University of Salamanca and by the Bioethics Subcommittee of 
Consejo Superior de Investigaciones Cientiﬁ cas (CSIC). Both male 
and female WT and  Pax5 +/− mice of a mixed C57BL/6 × CBA back-
ground were included in the study. We used WT and  Pax5 +/− litterma-
tes of the same breeding. Upon signs of disease, mice were sacriﬁ ced 
and subjected to standard necropsy procedures. All major organs 
were examined under the dissecting microscope. Tissue samples were 
taken from homogenous portions of the resected organ and ﬁ xed 
immediately after excision. Differences in Kaplan–Meier survival 
plots of transgenic and WT mice were analyzed using the log-rank 
(Mantel–Cox) test. 
 FACS Analysis 
 Nucleated cells were obtained from total mouse BM (ﬂ ushing from 
the long bones), PB, thymus, or spleen. Contaminating red blood 
cells were lysed with red cell lysis buffer, and the remaining cells were 
washed in PBS with 1% fetal calf serum (FCS). After staining, all cells 
were washed once in PBS and were resuspended in PBS with 1% FCS 
containing 2 mg/mL propidium iodide (PI) to allow dead cells to be 
excluded from both analyses and sorting procedures. The samples and 
the data were acquired in an AccuriC6 Flow Cytometer and analyzed 
using FlowJo software. Speciﬁ c ﬂ uorescence of FITC, Phycoerythrin, 
PI, and Allophycocyanin excited at 488 nm (0.4 W) and 633 nm (30 
mW), respectively, as well as known forward and orthogonal light 
scattering properties of mouse cells, were used to establish gates. 
Nonspeciﬁ c antibody binding was suppressed by preincubation of 
cells with CD16/CD32 Fc-block solution (BD Biosciences). For each 
analysis, a total of at least 50,000 viable (PI − ) cells was assessed. 
 The following antibodies were used for ﬂ ow cytometry: anti-B220 
(RA3-6B2), CD3ε (145-2C11), CD4 (RM4-5; 1:500), CD8a (53-6.7; 
1:500), CD11b/MAC1 (M1/70; 1:200), CD19 (1D3), CD117/c-KIT 
(2B8; 1:200), CD127/IL7Rα (A7R34; 1:50), Ly-6G/Gr1 (RB6-8C5), 
IgM (R6-60.2), SCA1/Ly-6A/E (E13-161.7; 1:50), CD25 (PC61), 
CD48 (HM48-1), and CD150 (TC15-12F12.2). Unspeciﬁ c anti-
body binding was suppressed by preincubation with CD16/CD32 
(2.4G2) Fc-block solution (PharMingen). The different hematopoi-
etic progenitors and B-cell stages were deﬁ ned by ﬂ ow cytometry 
as shown in  Supplementary Fig. S2A and S2B. All antibodies were 
purchased from BD Biosciences and used at a 1:100 dilution unless 
otherwise indicated. 
 Histology 
 Animals were sacriﬁ ced by cervical dislocation; tissue samples were 
formalin-ﬁ xed and embedded in parafﬁ n. Pathology assessment was 
performed on hematoxylin–eosin-stained sections under the supervi-
sion of Dr. Oscar Blanco, an expert pathologist at the Salamanca 
University Hospital. 
 V(D)J Recombination 
 Immunoglobulin rearrangements were ampliﬁ ed by PCR using the 
primers below. Cycling conditions consisted of an initial heat activa-
tion at 95°C followed by 31 to 37 cycles of denaturation for 1 minute 
at 95°C, annealing for 1 minute at 65°C, and elongation for 1 minute 
45 seconds at 72°C. This was followed by a ﬁ nal elongation for 10 
minutes at 72°C. To determine the DNA sequences of individual 
V(D)J rearrangements, the PCR fragments were isolated from the aga-
rose gel and cloned into the pGEM-Teasy vector (Promega); the DNA 
inserts of at least ten clones corresponding to the same PCR fragment 
were then sequenced. The following primer pairs were used: V H J558: 
forward CGAGCTCTCCARCACAGCCTWCATGCARCTCARC, reverse 
GTCTAGATTCTCACAAGAGTCCGATAGACCCTGG; V H 7183: forward 
CGGTACCAAGAASAMCCTGTWCCTGCAAATGASC, reverse GTCTA
GATTCTCACAAGAGTCCGATAGACCCTGG; V H Q52: forward CGGT
ACCAGACTGARCATCASCAAGGACAAYTCC, reverse GTCTAGATTC
TCACAAGAGTCCGATAGACCCTGG; GH: forward TTCAAAGCACA
ATGCCTGGCT, reverse GTCTAGATTCTCACAAGAGTCCGATAGAC
CCTGG; and Cμ: forward TGGCCATGGGCTGCCTAGCCCGGGACTT, 
reverse GCCTGACTGAGCTCACACAAGGAGGA. 
 Microarray Data Analysis 
 Total RNA was isolated in two steps using TRIzol (Life Technolo-
gies) followed by RNeasy Mini-Kit (Qiagen) puriﬁ cation, follow-
ing the manufacturer’s RNA Clean-up Protocol with the optional 
On-Column DNase treatment. The integrity and the quality of the 
RNA were veriﬁ ed by electrophoresis, and its concentration was 
measured. Samples were analyzed using Affymetrix Mouse Gene 
1.0 ST arrays. 
 Brieﬂ y, the robust microarray analysis algorithm was used for 
background correction, intra- and intermicroarray normalization, 
and expression signal calculation ( 38–40 ). Once the absolute expres-
sion signal for each gene (i.e., the signal value for each probe set) was 
calculated in each microarray, a method called signiﬁ cance analysis 
of microarray ( 41 ) was applied to calculate signiﬁ cant differential 
expression and ﬁ nd the gene probe sets that characterized the tumor-
bearing BM from  Pax5 +/− mice compared with BM-derived B220 + cells 
from WT mice. The method uses permutations to provide robust sta-
tistical inference of the most signiﬁ cant genes and provides  P values 
adjusted to multiple testing using FDR ( 42 ). A cutoff of FDR < 0.05 
was used for the differential expression calculations. We applied all 
these methods using R and Bioconductor ( 43 ). 
 The data discussed in this publication have been deposited in 
NCBI’s Gene Expression Omnibus ( GEO; ref. 44 ) and are accessible 
through GEO Series accession number GSE62529. 
 Enrichment Analysis 
 Differentially expressed genes were tested for enrichment using 
GSEA from MSigDB ( 21 ). Gene expression signatures that are spe-
ciﬁ cally upregulated or downregulated in human B-ALL gene sets 
( 18, 19 ) were also assessed for their overlap with those that were 
upregulated or downregulated within tumor specimens using GSEA. 
We also carried out more enrichment analysis for the speciﬁ c normal 
murine B-cell stage signatures ( 20 ). Finally, we carried out one more 
enrichment analysis for the speciﬁ c  Pax5 gene signatures described 
in refs.  23 and  45–47 . 
 Cdkn2a/Arf Expression 
 cDNA was synthesized from BM tumor cells of  Pax5 +/− mice 
using the High Capacity RNA-to-cDNA Kit and used for TaqMan 
gene expression assays. For quantitative PCR, the following TaqMan 
Gene Expression Assay (Applied Biosystems) was used:  Cdkn2a / Arf 
(Mm.PT.56a.8388138).  Gadph (Mm.PT.39a.1) was used as an internal 
control. 
 Detection of Viral Integration 
 The Genome Information Broker for Viruses (GIB-V) was screened 
for viral sequences. The database comprises the genomes of 25,525 
clones and strains of DNA and RNA viruses (mouse and human). The 
virus detection can be divided into three steps: retrieve potential viral 
sequences, ﬁ lter low-quality detections, and analyze paired-end reads 
for viral integration. Reads, which could not be mapped against the 
mouse reference genome (GRCm38) with Burrows-Wheeler Aligner 
Research. 
on January 12, 2016. © 2015 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst September 25, 2015; DOI: 10.1158/2159-8290.CD-15-0892 
1340 | CANCER DISCOVERYDECEMBER  2015 www.aacrjournals.org
Martín-Lorenzo et al.RESEARCH ARTICLE
(BWA) at default and with Bowtie 2 at high sensitivity (minimum 
mapping concordance of 85%), are candidates for sequences of other 
(e.g., viral) origin. Hence, they were further inspected for sequence 
similarity with genomes in the GIB-V database using Bowtie 2 
with the following parameters: bowtie2 –very-sensitive –mp 1,1 –rdg 
2,1 –rfg 2,1 –score-min L,0,–0.15. 
 Reads could be mapped to multiple viruses or strains of the 
same virus to avoid missing alignments due to sequence similarity 
between the viral sequences. The viral genomes were analyzed for low 
complexity and repetitive regions with RepeatMasker and compared 
with the mouse reference genome with the Nucmer algorithm in 
the MUMmer package. Low-quality alignments within repeats or 
regions with high sequence homology with the mouse genome were 
discarded as well as multiple alignments of one read against the 
same viral genome. Paired-end reads, where one mate mapped to 
the mouse genome and the other mate to a virus, hinted at possible 
viral integration spots. Candidates, like the integration on  Pax5 , were 
investigated manually with the Integrative Genomics Viewer to pin-
point the exact breakpoints. 
 Mouse Exome Library Preparation and Next-Generation 
Sequencing 
 Sample Acquisition  The AllPrep DNA/RNA Mini Kit (Qiagen) 
was used to purify DNA according to the manufacturer’s instruc-
tions. 
 Exome Library Preparation and Next-Generation Sequencing  Exome 
library preparation was performed using the Agilent SureSelectXT 
Mouse All Exon Kit with modiﬁ cations. Targeted capture by hybridiza-
tion to an RNA library was performed according to the manufacturer’s 
protocol. Puriﬁ cation and enrichment of the captured library were 
achieved by binding to MyOne Streptavidin T1 Dynabeads (Life Tech-
nologies) and off-bead PCR ampliﬁ cation in the linear range. Sequenc-
ing (2 × 100 bp) with a 6-bp index read was performed using the TruSeq 
SBS Kit v3 on the HiSeq 2500 (Illumina). 
 Data Analysis  Fastq ﬁ les were generated by using BcltoFastq 
1.8.4 (Illumina). BWA version 0.7.4. was used to align sequence data 
to the mouse reference genome (GRCm38.71). Conversion steps 
were carried out using SAMtools followed by removal of duplicate 
reads. Local realignment around indels, SNP-calling, annotation, 
and recalibration was facilitated by GATK 2.4.9. Mouse dbSNP138 
and dbSNP for the used mouse strains were used as training datasets 
for recalibration. Resulting variation calls were annotated by Variant 
Effect Predictor using the Ensembl database (v70) and imported into 
an in-house MySQL database to facilitate automatic and manual 
annotation, reconciliation, and data analysis by complex database 
queries. Loss-of-function prediction scores for PolyPhen2 and SIFT 
were extracted from this Ensembl release. 
 Somatic calls were produced using MuTect ( 48 ) and VarScan ( 49 ). For 
VarScan2 results, false-positive ﬁ ltering as suggested by the author was 
applied. To clear the resulting ﬁ le of suspicious-looking results, only 
entries with at least 9% difference in allele frequency between tumor and 
normal were kept for further analysis. Cancer-related genes were deter-
mined by translating the cancer gene consensus from the Catalogue 
of Somatic Mutations in Cancer (COSMIC) using Ensembl’s BioMart. 
 Sequencing 
 Mutations were validated using Sanger sequencing on a 3130 
Genetic Analyzer (Applied Biosystems). The following primer 
pairs were used:  mJak3 forward: CGGGATGTGGGGCTTTAACT, 
reverse: GCAGACACGGGGTATAGTGG;  mJak1 forward: CCA
GACAGCCAGGAGAACAG, reverse: CGTCTGCATAGTACCCACCC; 
 mPax5 forward: CTCGTACATGCACGGAGACA, reverse: GGAC
CCTTCAGTACACCAGC. 
 Deep Sequencing 
 For deep sequencing, Illumina TruSeq Adapters were used with 
the following product-speciﬁ c primers:  mJak3 R653H/C forward: 
CCCTGTTCCCTCCTGTAACAC, reverse: AGTGGGACTGACAC
CAGGAT;  mJak3 V670A forward: AACGTCTCAGCACGGAAGG, 
reverse: GTGCAAAGGTGACCATGACAG. Samples were sequenced 
on a HiSeq 2500 (Illumina Inc.). 
 Ba/F3 Experiments 
 Cell Lines  Ba/F3 cells were directly obtained from the cell bank 
DMSZ (ACC 300; Heidelberg). The cells were maintained according 
to the supplier’s instructions, authenticated by the company, and 
used within 6 months of receipt. Species speciﬁ city was documented 
by PCR, and the cell line was characterized by morphology, FACS 
analysis, and cytogenetics. No authentication has been done by the 
authors. Cells were cultivated in RPMI-1640 Medium GlutaMAX 
(Life Technologies), supplemented with 10% (v/v) heat-inactivated 
FCS, Gentamycin (50 μg/mL), and recombinant mouse IL3 (10 μg/
mL; Life Technologies), at 37 °C and 5% CO 2 . 
 Generation of Murine  Jak3 R653H  A cDNA encoding the coding 
sequence of the WT murine  Jak3 was obtained from the Riken Full 
Length cDNA Clone A130091E14 (Source Bioscience) via PCR using 
the Phusion High-Fidelity DNA Polymerase (Thermo Scientiﬁ c). The 
mutant cDNA for murine  Jak3 R653H was created by site-directed mutagen-
esis by PCR ( mJak3 WT forward: GGCGCACGCGTATGGCACCTCCAAGT
GAGG, reverse: CCTCGGGGCCCTCCGGGTCTTCCACGCCAC;  mJak3 R653H 
forward: CGGAAGGTGCTCCTGGCTCATGAGGGGGGTGATGGG
AATC; reverse: GATTCCCATCACCCCCCTCATGAGCCAGGAGCAC
CTTCCG). The WT and mutant murine  Jak3 sequences were cloned 
into a derivative of a bicistronic expression vector (pMC3) used previ-
ously for stable expression of genes in cell lines. Here, the vector was 
modiﬁ ed to encode the Hygromycin resistance gene as the second 
cistron (pMC3-JAK3.Hygro). 
 Ba/F3 cells were transfected using the Amaxa Nucleofector Tech-
nology (Lonza), according to the manufacturer’s protocol. Cells 
harboring the plasmids were selected using 600 μg/mL Hygromycin 
B (Life Technologies). To examine the PAX5-independent potential 
role of the identiﬁ ed  Jak3 mutations in leukemogenesis, we injected 
Ba/F3 cells expressing either  Jak3 V670A ( n = 5) or  Jak3 R653H ( n = 4) in the 
tail vein of nude mice as previously described ( 50 ). 
 Proliferation Assay 
 Ba/F3 cells (2 × 10 5 ) expressing either murine  Jak3 WT ,  Jak3 R653H , 
or the empty vector control were washed twice with medium 
without IL3, before they were cultured in the absence of IL3 for 
10 days.  Pax5 +/− ( Jak3 V670A ),  Pax5 +/− , and WT pro-B cells (1 × 10 4 ) 
were washed twice with medium without IL7, before they were 
cultured in the absence of IL7 for 7 days. Proliferation was 
measured by counting the cells every day using Trypan Blue 
(Sigma-Aldrich). 
 Immunoblot Analysis 
 Whole-cell extracts were obtained as previously described ( 28 ). 
Spleen samples were prepared using a 100-μm cell strainer and 
depleted of erythrocytes using NH 4 Cl, before lymphocytes were 
lysed in RIPA buffer (50 mmol/L Tris, pH 8.0, 150 mmol/L NaCl, 
0.5% Sodiumdeoxycholate, 1% NP-40 substitute, 0.1% SDS) con-
taining protease and phosphatase inhibitors (Roche Diagnostics). 
Whole protein (20 μg) was separated on SDS-PAGE and transferred 
to Hybond-C Extra membranes (Amersham Biosciences). Immuno-
blotting was carried out using the following antibodies: anti–
phospho-STAT5 (1:1,000), anti-STAT5 (1:1,000; Cell Signaling), and 
anti–β-actin clone AC-74 (1:10,000; Sigma-Aldrich). Detection was 
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done using anti-rabbit or anti-mouse horseradish peroxidase con-
jugates (Santa Cruz Biotechnology), respectively, with an enhanced 
chemiluminescence system (Thermo Scientiﬁ c). 
 Pro–B-cell Culture 
 Iscove’s Modiﬁ ed Dulbecco’s Medium (IMDM) supplemented with 
50  μmol/L β-mercaptoethanol, 1 mmol/L  L -glutamine, 2% heat-inac-
tivated FCS, 1 mmol/L penicillin–streptomycin (BioWhittaker), and 
0.03% (w/v) primatone RL (Sigma) was used for pro–B-cell culture 
experiments. Pro-B cells isolated by magnetic-activated cell sorting for 
B220 + (Milteny Biotec) from BM were cultured on Mitomycin C–treated 
ST2 cells in IMDM medium containing IL7 (R&D Systems). IL7-inde-
pendent tumor pro-B cells were grown in the same medium without IL7. 
 Inhibitor Experiments 
 WT,  Pax5 +/− , and tumor pro-B cells were seeded at 10 6 /3 mL/well in 
6-well plates and treated with or without (vehicle) tofacitinib (JAK1/3 
inhibitor; 1 μmol/L), TG101348 (JAK2 inhibitor; 1 μmol/L), and 
ruxolitinib (JAK1/2 inhibitor; 1 μmol/L) for 24 hours before being 
subjected to cell viability assay. Experiments were performed at the 
same time under the same experimental conditions. 
 Apoptosis Assays 
 Aliquots (200 μL) containing 10 6 cells in 10 mmol/L Hepes/NaOH, 
ph 7.4, 140 mmol/L NaCl, and 2.5 mmol/L CaCl2 were incubated 
with Annexin V–FITC (BD Biosciences) to a ﬁ nal concentration of 
1 μg/mL for 10 minutes, at room temperature in the dark, and then 
labeled with PI to a ﬁ nal concentration of 2 μg/mL (PI in binding 
buffer). Flow cytometry was performed within an hour of label-
ing, and data were analyzed using FlowJo software. The difference 
between experimental variables was determined using the Student 
 t test. 
 BM Transplantation Experiments 
 BM myeloid cells,  Pax5 +/− pro-B cells with intact  Jak3 , and  Pax5 +/− 
proB cells harboring the  Jak3 V670A mutation were injected intra-
venously into sublethally irradiated (4 Gy) secondary recipient 
12-week-old male syngenic mice (C57BL/6 × CBA). Disease develop-
ment in the recipient mice was monitored by periodic PB analysis 
until blast cells were detected. Then, they were sacriﬁ ced and assessed 
for pB-ALL development. 
 Preclinical Therapeutics 
 Ruxolitinib prepared in PBS was administered at 180 mg/kg, 
orally, twice a day, when animals had developed a signiﬁ cant leuke-
mic burden as documented by FACS analysis of PB. Disease develop-
ment in the recipient mice was monitored by periodic PB analysis 
until blast cells were detected. Then they were sacriﬁ ced and assessed 
for pB-ALL development. 
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